Compare RVSB & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RVSB | HURA |
|---|---|---|
| Founded | 1923 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.5M | 123.0M |
| IPO Year | 1997 | 2010 |
| Metric | RVSB | HURA |
|---|---|---|
| Price | $6.11 | $1.63 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.04 |
| AVG Volume (30 Days) | 68.8K | ★ 392.5K |
| Earning Date | 10-27-2026 | 11-17-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | N/A | ★ 47.93 |
| EPS | ★ 0.08 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.74 | N/A |
| Revenue Next Year | $5.53 | N/A |
| P/E Ratio | $76.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.88 | $0.41 |
| 52 Week High | $6.22 | $3.43 |
| Indicator | RVSB | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 63.19 | 38.17 |
| Support Level | $5.23 | $1.27 |
| Resistance Level | $6.22 | $2.22 |
| Average True Range (ATR) | 0.11 | 0.19 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 70.97 | 8.96 |
Riverview Bancorp Inc is the bank holding company. The Company's operations are managed along two operating segments, consisting of banking operations performed by the Bank and trust and investment services performed by the Trust Company. The Bank is engaged mainly in the business of attracting deposits from the general public and using such funds, together with other borrowings, to make various commercial business, commercial real estate, land, multi-family real estate, real estate construction and consumer loans. Additionally, the Trust Company offers trust and investment. Its operations into two operating segments, consisting of banking operations and trust and investment services, these operating segments are aggregated into a single reportable operating segment.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.